Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs
Authors:
- 17 July 2006
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 541 (3) , 171-176
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic PropertiesCirculation, 2004
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004
- Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical TrialsJournal of Cardiovascular Pharmacology and Therapeutics, 2004
- Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized Controlled TrialJAMA, 2004
- Treatment of Erectile Dysfunction in Patients with Cardiovascular DiseaseDrugs, 2004
- The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A ThiolaseCirculation Research, 2003
- ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary articleJACC, 2003
- Effects of nitroglycerin treatment on baroreflex sensitivity andshort-term heart rate variability in humansJACC, 2002
- Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable AnginaJAMA, 1999
- Angina Pectoris in a Contemporary Population: Characteristics and Therapeutic ImplicationsCardiovascular Drugs and Therapy, 1998